Abstract:All organisms growing beyond the oxygen diffusion limit critically depend on a functional vasculature for survival. Yet blood vessels are far more than passive, uniform conduits for oxygen and nutrient supply. A remarkable organotypic heterogeneity is brought about by tissue-specific differentiated endothelial cells (lining the blood vessels’ lumen) and allows blood vessels to deal with organ-specific demands for homeostasis. On the flip side, when blood vessels go awry, they promote life-threatening diseases characterized by endothelial cells inappropriately adopting an angiogenic state (eg, tumor vascularization) or becoming dysfunctional (eg, diabetic microvasculopathies), calling respectively for antiangiogenic therapies and proangiogenic/vascular regenerative strategies. In solid tumors, despite initial enthusiasm, growth factor–based (mostly anti-VEGF [vascular endothelial growth factor]) antiangiogenic therapies do not sufficiently live up to the expectations in terms of efficiency and patient survival, in part, due to intrinsic and acquired therapy resistance. Tumors cunningly deploy alternative growth factors than the ones targeted by the antiangiogenic therapies to reinstigate angiogenesis or revert to other ways of securing blood flow, independently of the targeted growth factors. In trying to alleviate tissue ischemia and to repair dysfunctional or damaged endothelium, local in-tissue administration of (genes encoding) proangiogenic factors or endothelial (stem) cells harnessing regenerative potential have been explored. Notwithstanding evaluation in clinical trials, these approaches are often hampered by dosing issues and limited half-life or local retention of the administered agents. Here, without intending to provide an all-encompassing historical overview, we focus on some recent advances in understanding endothelial cell behavior in health and disease and identify novel molecular players and concepts that could eventually be considered for therapeutic targeting.

Targeted therapies for vascular malformations

Research Progress on Targeted Drugs for Vascular Malformations

Vascular anomalies in childhood. Review and update

The Role of Medical Management in Vascular Anomalies

Defining the Role of Oral Pathway Inhibitors as Targeted Therapeutics in Arteriovenous Malformation Care

Current trends, molecular insights, and future directions toward precision medicine in the management of pediatric cerebral arteriovenous malformations

Pearls and Pitfalls in the Management of Vascular Anomalies

Magnetic resonance – guided treatment of low-flow vascular malformations and the technologies to potentiate adoption

What the Interventional Radiologist Needs to Know about the Genetics of Vascular Anomalies

Advances in vascular anomalies: refining classification in the molecular era

Progress in the Genetics Research of Infantile Hemangioma and Vascular Malformations

Progress in evidence-based research on the clinical treatment of infantile hemangioma and vascular malforma-tions

Update on the Molecular Genetics of Vascular Anomalies

Managing Vascular Anomalies In The Era Of Genetics And Precision Medicine An Opportunity Or A Challenge?

Arteriovenous Malformations—Current Understanding of the Pathogenesis with Implications for Treatment

Advancement of genetics and target therapy of extracranial arteriovenous malformation

Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering

Basic and Therapeutic Aspects of Angiogenesis Updated

Infantile Hemangiomas and Vascular Anomalies

The expansion of liquid biopsies to vascular care: an overview of existing principles, techniques and potential applications to vascular malformation diagnostics

Vascular-specific growth factors and blood vessel formation